Direct-Acting Antiviral Agents. Regimens for the Interferon Failure Patient.

Tatyana Kushner, Vandana Khungar

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Over the past few years, tremendous advances have been made in the treatment of hepatitis C with direct-acting antiviral agents (DAAs), allowing treatment options for patients who have failed prior treatment with interferon. In addition to interferon's severe adverse effect profile, and the inability of many patients to tolerate it, prior interferon-containing regimens were not as effective in achieving sustained virologic response as emerging therapies. New DAAs have demonstrated higher rates of sustained virologic response, shorter duration of treatment, and improved adverse effect profile.

Original languageEnglish
Pages (from-to)629-639
Number of pages11
JournalClinics in Liver Disease
Issue number4
StatePublished - Nov 2015
Externally publishedYes


  • Direct-acting antivirals
  • Hepatitis C
  • Interferon
  • Treatment


Dive into the research topics of 'Direct-Acting Antiviral Agents. Regimens for the Interferon Failure Patient.'. Together they form a unique fingerprint.

Cite this